November 2014

New Product - Olysio

Olysio (simeprevir) is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease which is essential for viral replication. Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection. Olysio in combination with peginterferon alfa and ribavirin is contraindicated in women who are or may become pregnant. Ribavirin may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug treatment, the patient should be apprised of the potential hazard to a fetus. It is also contraindicated in men whose female partners are pregnant. Olysio is available in 150 mg capsules in blister strips of 7’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629